We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+8.97%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$425M
AUM Growth
-$23.3M
(-5.2%)
Cap. Flow
+$28.2M
Cap. Flow
% of AUM
6.64%
Top 10 Holdings %
Top 10 Hldgs %
49.03%
Holding
60
New
17
Increased
11
Reduced
11
Closed
10
Top Buys
| 1 |
Kura Oncology
KURA
|
+$8.7M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$6.55M |
| 3 |
Gyre Therapeutics
GYRE
|
+$6.09M |
| 4 |
Celldex Therapeutics
CLDX
|
+$5.74M |
| 5 |
Viridian Therapeutics
VRDN
|
+$5.62M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
+$12.9M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$10.6M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$9.61M |
| 4 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
+$9.24M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$8.51M |
Sector Composition
| 1 | Healthcare | 77.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMRN
51
Amarin Corp
AMRN
$292M
| – | – |
-20,000
| Closed | -$1.96M |
|
|
KALV
52
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-200,000
| Closed | -$3.8M |
|
53
PUT
Moderna
MRNA
$24.5B
| – | – |
-35,000
| Closed | -$3.66M |
|
54
Sarepta Therapeutics
SRPT
$1.82B
| – | – |
-40,000
| Closed | -$6.82M |
|
55
Tempest Therapeutics
TPST
$15.4M
| – | – |
-4,744
| Closed | -$1.98M |
|
|
56
Travere Therapeutics
TVTX
$5.27B
| – | – |
-475,000
| Closed | -$12.9M |
|
57
Wave Life Sciences
WVE
$1.12B
| – | – |
-200,000
| Closed | -$1.57M |
|
|
MRTX
58
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-50,000
| Closed | -$11M |
|
|
SURF
59
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| – | – |
-1,000,000
| Closed | -$9.24M |
|
|
FPRX
60
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-500,000
| Closed | -$8.51M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2021 Portfolio in Review
As of Q1 2021, Ghost Tree Capital held 60 positions worth $425M, down 5.2% from $449M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Ghost Tree Capital deployed $28.2M of net new capital in Q1 2021, opening 17 new positions and adding to 11 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 30,000 shares worth $6.63M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 83% a quarter earlier.
On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $10.6M trimmed.
- Ghost Tree Capital's largest Q1 2021 buy was iShares Russell 2000 ETF: 30,000 shares worth $6.63M.
- Ghost Tree Capital added most to Kura Oncology in Q1 2021, an estimated $8.7M increase.
- Ghost Tree Capital's biggest Q1 2021 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $10.6M.
- Ghost Tree Capital fully exited Travere Therapeutics in Q1 2021, selling an estimated $12.9M.
- Ghost Tree Capital's ten largest holdings make up 49% of its $425M portfolio in Q1 2021.
- Ghost Tree Capital opened 17 new positions and closed 10 in Q1 2021.
- Ghost Tree Capital's portfolio value fell 5.2% quarter-over-quarter to $425M.
Based on Ghost Tree Capital's 13F filing for Q1 2021, filed 14 May 2021.